Iovance downgraded to Neutral at UBS related to Amtagvi concerns

alexsl

Iovance Biotherapeutics (NASDAQ:IOVA) has been downgraded to Neutral from Buy at UBS, reflecting growing uncertainty around the commercial rollout of its cell therapy, Amtagvi.

The analysts at UBS say that despite the initial excitement following approval, recent financial and operational updates